Lewy body dementia gets its name from Fritz Heinrich Lewy, a German-American neurologist who first described unusual clumps of protein inside brain cells in 1912. These microscopic deposits, later named “Lewy bodies” in his honor, are the defining feature of the disease. When enough of them accumulate in the brain, they cause the progressive cognitive decline, visual hallucinations, and movement problems that characterize this form of dementia.
The Neurologist Behind the Name
Fritz Heinrich Lewy was working in Alois Alzheimer’s laboratory in Munich when he made his discovery. While studying the brains of patients who had died with Paralysis agitans (the term used for Parkinson’s disease at the time), Lewy noticed abnormal round deposits inside nerve cells. These inclusions were unlike anything previously described. The scientific community eventually named them “Lewy bodies,” and decades later, when researchers found the same deposits widespread in the brains of people with a distinct type of dementia, the condition itself inherited his name.
What Lewy Bodies Actually Are
Lewy bodies are tiny clumps built primarily around a protein called alpha-synuclein. In a healthy brain, this protein helps nerve cells communicate by assisting with the release of chemical signals at synapses. But in Lewy body dementia, alpha-synuclein misfolds and sticks together, forming dense clusters inside neurons.
These clumps do far more damage than simply sitting in the way. As Lewy bodies form and mature, they trap essential cellular machinery inside them, including the cell’s energy-producing structures (mitochondria) and the transport systems that shuttle chemical signals between neurons. This hijacking starves the cell of the tools it needs to function. Research published in PNAS showed that the formation process itself, not just the protein clumping, is a major driver of nerve cell death. The Lewy bodies essentially choke neurons from the inside out, disrupting their energy supply and their ability to communicate with neighboring cells.
This is fundamentally different from what happens in Alzheimer’s disease, where the hallmark features are sticky plaques that build up between neurons and tangled fibers inside them, made from different proteins entirely. Lewy bodies represent a separate disease process, which is why the two conditions produce different symptom patterns.
How the Disease Affects the Brain
As Lewy bodies spread through the brain, they damage the chemical messenger systems that control thinking, movement, mood, and sleep. The nerve cells that produce dopamine (critical for movement and motivation) and acetylcholine (essential for attention and memory) are particularly vulnerable. Losing both of these systems at once explains why people with Lewy body dementia experience such a wide range of symptoms, from stiff, slow movement to confusion and vivid hallucinations.
The damage to synapses, the junctions where neurons talk to each other, is dramatic. Lab studies have measured steep drops in markers of synaptic health as Lewy body-like inclusions form. When neurons can no longer send or receive signals effectively, cognitive function deteriorates. This synaptic breakdown also helps explain one of the disease’s most distinctive features: fluctuating cognition, where a person can seem relatively sharp one hour and profoundly confused the next.
Two Conditions on One Spectrum
Lewy body dementia is actually an umbrella term covering two related diagnoses: dementia with Lewy bodies (DLB) and Parkinson’s disease dementia. Both involve the same Lewy body pathology, and many experts consider them part of a single spectrum rather than entirely separate diseases. The key difference is timing.
In dementia with Lewy bodies, cognitive problems and movement symptoms appear within roughly a year of each other, with thinking difficulties often showing up first. In Parkinson’s disease dementia, movement symptoms like tremor and rigidity come first, and cognitive decline typically doesn’t develop until 10 to 15 years later. The underlying biology is the same. What differs is where in the brain the Lewy bodies gain a foothold first and how quickly they spread.
Core Symptoms Used for Diagnosis
Diagnosing DLB relies on identifying a cluster of characteristic features. The central requirement is progressive cognitive decline significant enough to interfere with daily life. Beyond that, clinicians look for three core features: fluctuating cognition (unpredictable shifts in alertness and attention), recurrent visual hallucinations that are typically detailed and well-formed, and parkinsonism (movement symptoms like stiffness, slowness, or tremor). Having two of these three core features points to a probable diagnosis. One core feature makes it possible.
A fourth symptom, REM sleep behavior disorder, has become increasingly recognized as an early warning sign. People with this condition physically act out their dreams during sleep, sometimes thrashing, kicking, or shouting. Up to 76% of people with DLB experience it, and on average it appears about 8 years before the cognitive or motor symptoms that lead to a formal diagnosis. For many people, it’s the earliest detectable sign that Lewy bodies are forming in the brain.
How Lewy Bodies Are Now Detected
For most of medical history, the only way to confirm Lewy bodies existed in someone’s brain was through autopsy. That has started to change. A skin biopsy test can now detect the misfolded alpha-synuclein protein in nerve fibers just beneath the skin’s surface. In clinical testing, this biopsy correctly identified 96% of people with DLB and came back negative 97% of the time in healthy volunteers. Brain imaging that measures dopamine activity in specific regions can also support a diagnosis, since reduced dopamine transporter uptake is a hallmark of Lewy body disease.
These advances matter because Lewy body dementia accounts for an estimated 4 to 16% of all dementia cases seen in clinical settings, making it one of the most common forms of degenerative dementia after Alzheimer’s. Most diagnoses occur in people over 50, with older age being the single greatest risk factor. Despite its prevalence, it remains widely underdiagnosed, partly because its symptoms overlap with both Alzheimer’s and Parkinson’s disease. Having a name that ties the condition to a specific, identifiable protein deposit has helped sharpen that distinction, both for researchers working on targeted treatments and for the families trying to understand what’s happening to someone they love.